Cargando…

Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study

INTRODUCTION: Disease behaviour may guide diagnosis and treatment decisions in patients with interstitial lung disease (ILD). STARLINER aimed to characterise disease behaviour in patients with suspected ILD during the peri-diagnostic period using real-time home-based assessments. METHODS: STARLINER...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wijsenbeek, Marlies S., Bendstrup, Elisabeth, Valenzuela, Claudia, Henry, Michael T., Moor, Catharina C., Jouneau, Stéphane, Fois, Alessandro G., Moran-Mendoza, Onofre, Anees, Syed, Mirt, Mirela, Bengus, Monica, Gilberg, Frank, Kirchgaessler, Klaus-Uwe, Vancheri, Carlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195454/ https://www.ncbi.nlm.nih.gov/pubmed/34117601 http://dx.doi.org/10.1007/s12325-021-01790-y

Ejemplares similares

Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study
por: Wijsenbeek, Marlies, et al.
Publicado: (2018)

A review of the challenges, learnings and future directions of home handheld spirometry in interstitial lung disease
por: Maher, Toby M., et al.
Publicado: (2022)

Managing Fatigue in Patients With Interstitial Lung Disease
por: Kahlmann, Vivienne, et al.
Publicado: (2020)

Role of the internet of medical things in care for patients with interstitial lung disease
por: Nakshbandi, Gizal, et al.
Publicado: (2023)

Exhaled breath analysis in interstitial lung disease
por: van der Sar, Iris G., et al.
Publicado: (2023)

Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis
por: Glassberg, Marilyn K., et al.
Publicado: (2019)

Feasibility of online home spirometry in systemic sclerosis–associated interstitial lung disease: a pilot study
por: Moor, Catharina C, et al.
Publicado: (2020)

Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?
por: Kalluri, Meena, et al.
Publicado: (2021)

Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era
por: Nakshbandi, Gizal, et al.
Publicado: (2021)

Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis
por: Flaherty, Kevin R., et al.
Publicado: (2018)

Desquamative interstitial pneumonia: a systematic review of its features and outcomes
por: Hellemons, Merel E., et al.
Publicado: (2020)

Feasibility of a Comprehensive Home Monitoring Program for Sarcoidosis
por: Moor, Catharina C., et al.
Publicado: (2019)

Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis
por: Moor, Catharina C., et al.
Publicado: (2017)

Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population
por: Kahlmann, Vivienne, et al.
Publicado: (2021)

Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry
por: Moor, Catharina C., et al.
Publicado: (2020)

Differentiating interstitial lung diseases from other respiratory diseases using electronic nose technology
por: van der Sar, Iris G., et al.
Publicado: (2023)

Educational aspects of rare and orphan lung diseases
por: Alfaro, Tiago M., et al.
Publicado: (2021)

Comprehensive Care for Patients with Sarcoidosis
por: Moor, Catharina C., et al.
Publicado: (2020)

The 6-min walk test as a primary end-point in interstitial lung disease
por: Harari, Sergio, et al.
Publicado: (2022)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Risk Stratifying Interstitial Lung Abnormalities to Guide Early Diagnosis of Interstitial Lung Diseases
por: Wijsenbeek, Marlies S., et al.
Publicado: (2022)

Editorial: Interstitial Lung Disease Around the World
por: Wijsenbeek, Marlies, et al.
Publicado: (2022)

The world of rare interstitial lung diseases
por: Buschulte, Katharina, et al.
Publicado: (2023)

Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use
por: Kreuter, Michael, et al.
Publicado: (2021)

The use of online visual analogue scales in idiopathic pulmonary fibrosis
por: Moor, Catharina C., et al.
Publicado: (2022)

Research highlights from the 2018 ERS International Congress: interstitial lung diseases
por: Alfaro, Tiago M., et al.
Publicado: (2019)

Efficacy of Pirfenidone vs. Placebo in Unclassifiable Interstitial Lung Disease, by Surgical Lung Biopsy Status: Data From a post-hoc Analysis
por: Molina-Molina, Maria, et al.
Publicado: (2022)

Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases
por: Bonella, Francesco, et al.
Publicado: (2022)

The need for a holistic approach for SSc-ILD – achievements and ambiguity in a devastating disease
por: Hoffmann-Vold, Anna-Maria, et al.
Publicado: (2020)

ERS International Congress 2022: highlights from the Interstitial Lung Diseases Assembly
por: Karampitsakos, Theodoros, et al.
Publicado: (2023)

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis
por: Jouneau, Stéphane, et al.
Publicado: (2020)

ERS International Congress 2021: highlights from the Interstitial Lung Diseases Assembly
por: Guler, Sabina A., et al.
Publicado: (2022)

Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
por: Miedema, Jelle R., et al.
Publicado: (2022)

The flare of care for rare: per aspera ad astra for rare lung diseases!
por: Wijsenbeek, Marlies, et al.
Publicado: (2023)

Where are the gaps in education in the field of rare lung disease? Perspectives from the ERN-LUNG educational programme survey
por: Powell, Pippa, et al.
Publicado: (2019)

Cough in idiopathic pulmonary fibrosis
por: van Manen, Mirjam J.G., et al.
Publicado: (2016)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

Role of imaging in progressive-fibrosing interstitial lung diseases
por: Walsh, Simon L.F., et al.
Publicado: (2018)

Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study
por: Kahlmann, Vivienne, et al.
Publicado: (2020)

Study protocol of an international patient-led registry in patients with pulmonary fibrosis using online home monitoring: I-FILE
por: Nakshbandi, Gizal, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2quodtlchaqenfd3no0f1oflp8